The immunogenicity and safety of zoster vaccine in Taiwanese adults

Chien An Yao, Liang Kung Chen*, Kuo Chin Huang

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


The efficacy and safety of ZOSTAVAX™ in subjects 60 years of age and older was established in the Shingles Prevention Study (SPS) and in subjects 50 to 59 years of age in the ZOSTAVAX™ Efficacy and Safety Trial (ZEST). We evaluated the safety and immunogenicity of ZOSTAVAX™ in a total of 150 Taiwanese subjects ≥50 years of age, who received a single dose of ZOSTAVAX™. gpELISA was used to determine geometric mean titers (GMT) of the varicella-zoster virus (VZV) antibody. The geometric mean fold rise (GMFR) of the VZV antibody from the pre-vaccination to the 4 week post-vaccination time point was calculated. There was an overall increase in GMT from 128.45 to 391.85 at 4 weeks post-vaccination. The estimated GMFR was 3.05 (95% CI: 2.60 to 3.57).There were no serious adverse events for 28 days following vaccination. This study demonstrated the safety and immunogenicity of ZOSTAVAX™ among healthy Taiwanese adults.

Original languageEnglish
Pages (from-to)1515-1517
Number of pages3
Issue number13
StatePublished - 24 Mar 2015


  • Geometric mean fold rise
  • Herpes zoster
  • Immunogenicity
  • NCT00444860
  • Safety
  • Zoster vaccine


Dive into the research topics of 'The immunogenicity and safety of zoster vaccine in Taiwanese adults'. Together they form a unique fingerprint.

Cite this